The Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval of lecanemab.
This particular therapy is a monoclonal antibody treatment for use among patient populations with mild cognitive impairment or mild stages of dementia brought on by Alzheimer’s Disease (AD).
The approval signals further progress in addressing an unmet medical need.
Check out the rest of the feature here
